Clinical and sensorimotor gating effects of ketamine in normals

Neuropsychopharmacology

Volumn 25, Issue 1, 2001, Pages 72-83

  Duncan, Erica J ^a,b,d   Madonick, Steven H ^b   Parwani, Arti ^b   Angrist, Burt ^a,b   Rajan, Rajive ^a   Chakravorty, Subhajit ^a   Efferen, Toby R ^a   Szilagyi, Sandor ^a   Stephanides, Myrsini ^a   Chappell, Phillip B ^c   Gonzenbach, Stephen ^a   Ko, Grant N ^c   Rotrosen, John P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Acoustic startle; Habituation; Ketamine; Prepulse inhibition; Schizophrenia; Sensorimotor gating

Indexed keywords

KETAMINE; PLACEBO; SODIUM CHLORIDE;

ADULT; ARTICLE; CHANNEL GATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; MALE; NORMAL HUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX; STIMULUS RESPONSE;

ADULT; AFFECT; BRAIN; CARDIOVASCULAR PHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HALLUCINATIONS; HUMANS; KETAMINE; MALE; NEURAL INHIBITION; NEURONS; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE; REFERENCE VALUES; STARTLE REACTION;

EID: 0035017409     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00240-2     Document Type: Article

References (79)

1. A rating scale for emotional blunting
2. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers
3. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia
4. Effects of the PCP analog dizocilpine on sensory gating: Potential relevance to clinical subtypes of schizophrenia
5. Phencyclidine-induced psychosis
6. Affective flattening and the criteria for schizophrenia
7. Observations on the psychotomimetic effects of sernyl
8. Observations on the action of Sernyl - A new psychotropic drug
9. Sensorimotor gating and habituation evoked by electrocutaneous stimulation in schizophrenia
10. Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-trained rats
11. Sensorimotor gating and schizophrenia
12. Gating and habituation of the startle reflex in schizophrenic patients
13. Prestimulus effects on human startle reflex in normals and schizophrenics
14. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
15. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)
16. The glycine/NMDA receptor antagonist L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat
17. Discriminative stimulus properties of PCP mimetics
18. Cerebral glucography with positron tomography: Use in normal subjects and patients with schizophrenia
19. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography
20. Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs
21. Body image aberration in schizophrenia
22. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia
23. Inhibition of mammalian brain acetylcholinesterase by ketamine
24. Dysfunction in a prefrontal substrate of sustained attention in schizophrenia
25. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers
26. The neurophysiological basis of acoustic startle modulation: Research on fear motivation and sensory gating
27. Apomorphine, d-amphetamine, strychnine and yohimbine do not alter prepulse inhibition of the acoustic startle reflex
28. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats
29. A "glutamatergic hypothesis" of schizophrenia
30. Lack of sensitization to the effects of d-amphetamine and apomorphine on sensorimotor gating in rats
31. 99mTc-Exametazime in unmedicated schizophrenic patients
32. Regional brain glucose metabolism in chronic schizophrenia. A positron emission transaxial tomographic study
33. The more or less startling effects of weak prestimuli
34. Startle gating deficits occur across prepulse intensities in schizophrenic patients
35. NMDA-dependent modulation of CA1 Local circuit inhibition
36. Effect of d-amphetamine on prepulse inhibition of the startle reflex in humans
37. Effect of phencyclidine in chronic schizophrenia
38. The role of excitatory amino acids in neuropsychiatric illness
39. Recent advances in the phencyclidine model of schizophrenia
40. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: Effects of antipsychotics and other agents in rats
41. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle
42. Low cerebrospinal fluid glutamate in schizophrenics and a new hypothesis on schizophrenia
43. Rat strain differences in the ability to disrupt sensorimotor gating are limited to the dopaminergic system, specific to prepulse inhibition, and unrelated to changes in startle amplitude or nucleus accumbens dopamine receptor sensitivity
44. Role of the strychnine insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: A behavioral and microdialysis study
45. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
46. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics
47. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
48. Effects of local infusions of dopaminergic drugs into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine induced activity
49. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
50. Study of a new schizophrenomimetic drug - Sernyl
51. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
52. NMDA receptor function and human cognition: The effects of Ketamine in healthy volunteers
53. Effects of NMDA receptor ligands on sensorimotor gating in the rat
54. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat
55. Disorders of attention and perception in early schizophrenia
56. Glutamate receptor dysfunction and schizophrenia
57. Amphetamine sensitivity in open-field activity vs. the prepulse inhibition paradigm
58. The chiral forms of ketamine as probes for NMDA receptor functions in humans
59. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study
60. Impaired prepulse inhibition of acoustic startle in schizophrenics
61. Changes in prepulse inhibition after local administration on NMDA receptor ligands in the core region of the rat nucleus accumbens
62. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients
63. Amphetamine dose dependently disrupts prepulse inhibition of the acoustic startle response in rats within a narrow time window
64. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines
65. The interaction of ketamine with the opiate receptor
66. Limbic cortico-striato-pallido-pontine: Substrates of sensorimotor gating in animal models and psychiatric disorders
67. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats
68. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects
69. Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration
70. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia
71. 18F]fluorodeoxyglucose (FDG)
72. Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)
73. 2 or nucleus accumbens non-NMDA glutamate receptor activity
74. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates
75. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography
76. Negative symptoms and hypofrontality in chronic schizophrenia
77. Repeated administration of amphetamine induces sensitisation to its disruptive effect on prepulse inhibition in the rat
78. Role of dopamine in prepulse inhibition of acoustic startle